Improve diagnosis and treatment monitoring
-
JAK2Sensitive detection and quantification of the JAK2 V617F mutation to aid diagnosis of MPN. -
BCR-ABL1 MbcrHighly sensitive and reliable monitoring of IS-standardized molecular response to treatment in CML. -
BCR-ABL1 mbcrSensitive quantification of BCR-ABL1 mbcr for monitoring minimal/measurable residual disease (MRD) Ph+ ALL. -
PML-RARA bcr1Sensitive quantification of PML-RARA bcr1 for monitoring minimal/measurable residual disease in AML. -
WT1Sensitive quantification of Wilm's tumor (WT1) gene transcripts for monitoring minimal/measurable residual disease in AML.
-
Explore the power of oneMaximize the information derived from a single total nucleic acid sample by simultaneously preparing DNA and RNA libraries in one consolidated workflow.
With the new QIAseq Multimodal Leukemia Panel, you can simultaneously detect RNA fusions, exon skipping events and gene expression levels, along with SNVs, InDels, CNVs profiles, in a single, one-day workflow from as little as 10 ng of sample. -
Easily classify myeloid malignanciesQIAGEN Digital Insights clinical decision support software enables faster test turnaround times and higher confidence reporting for any indication on your sequencing platform.
QIAGEN Clinical Insight (QCI) Interpret provides transparent automation of blood cancer sub-classification and prognostic assessment, showing you how certain cancer subtypes potentially relate to therapeutic options.
ALL: Acute lymphoblastic leukemia; AML: Acute myeloid leukemia; CML: Chronic myeloid leukemia; CNV: Copy number variation; InDel: Inserstions/deletions; IS: International Scale; MPN: Myeloproliferative neoplasms; MRD: Minimal residual disease; NGS: Next-generation sequencing; Ph: Philadelphia chromosome; SNV: Single nucleotide variation.
The ipsogen JAK2 RGQ PCR Kit, ipsogen CALR RGQ PCR Kit, ipsogen BCR-ABL1 Mbcr RGQ RT-PCR Kit, ipsogen BCR-ABL1 mbcr Kit, ipsogen PML-RARA bcr1 Kit and ipsogen WT1 ProfileQuant Kit are intended for in vitro diagnostic use.
QIAseq Panels are intended for molecular biology applications. These products are not intended for the diagnosis, prevention, or treatment of a disease.
QCI Interpret is an evidence-based decision support software intended as an aid in the interpretation of variants observed in genomic next-generation sequencing data. The software evaluates genomic variants in the context of published biomedical literature, professional association guidelines, publicly available databases, annotations, drug labels, and clinical-trials. Based on this evaluation, the software proposes a classification and bibliographic references to aid in the interpretation of observed variants. The software is NOT intended as a primary diagnostic tool by physicians or to be used as a substitute for professional healthcare advice. Each laboratory is responsible for ensuring compliance with applicable international, national, and local clinical laboratory regulations and other specific accreditations requirements.
For up-to-date licensing information and product-specific disclaimers, see the respective QIAGEN kit handbook or user manual. QIAGEN kit handbooks and user manuals are available at www.qiagen.com or can be requested from QIAGEN Technical Services or your local distributor. QIAGEN is the exclusive licensee of intellectual property rights that cover the detection of the V617F JAK2 mutation (EP 1 692 281 and foreign counterparts) and CALR mutations (EP 2 808 338 and foreign counterparts) for diagnostic purposes.